Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum
22 Juni 2020 - 1:30PM
Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an
immuno-oncology company developing innovative drug candidates for
the prevention and treatment of cancer, today announced that it
will be presenting at Proactive One2One Virtual Investor Forum on
June 23, 2020.
Dr. Heman Chao, Chief Executive Officer of Helix
is scheduled to present on Tuesday, June 23rd at approximately
1:20pm Eastern Time. The presentation will be webcast live on the
conference event platform. You can access the invitation and
register to the Investor Forum with the following link:
https://www.proactiveinvestors.co.uk/companies/news/922066/biotech-companies-to-dominate-at-proactive-one2one-virtual-investor-forum-on-june-23-922066.html
About Proactive Investors
With offices in the US and in Canada, Proactive
Investors enables companies and investors to connect. The group is
one of the fastest growing financial media portals in the world,
providing breaking news, commentary and analysis on hundreds of
listed companies and pre-IPO businesses across the globe on a 24/7
basis. For more information: https://www.proactiveinvestors.com
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology
company specializing in the field of cancer therapy. Helix is a
biopharmaceutical company developing unique therapies in the field
of immuno-oncology, for the prevention and treatment of cancer,
based on its proprietary technology platform DOS47. Helix is
currently listed on the TSX under the symbol “HBP”. For more
information: https://www.helixbiopharma.com
Forward-Looking Statements and Risks and
Uncertainties
This news release may contain forward-looking
statements with respect to Helix, its operations, strategy,
financial performance and condition, including its activities
relating to its drug development program, any anticipated timelines
for the commencement or completion of certain activities such as
raising sufficient capital, merger and acquisition activity,
listing on a U.S. exchange and other information in future periods.
These statements generally can be identified by use of
forward-looking words such as “aims”, “transform”, “should”, “may”,
“will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or
“continue” or the negative thereof or similar variations. The
actual results and performance of discussed herein could differ
materially from those expressed or implied by such statements. Such
statements are qualified in their entirety by the inherent risks
and uncertainties surrounding future expectations, including: (i)
Helix’s ability to operate as a going concern being dependent
mainly on securing sufficient additional financing in order to fund
its ongoing research and development and other operating
activities; (ii) the generally inherent uncertainty involved in
scientific research and drug development and those specific to
Helix’s pre-clinical and clinical development programs (DOS47,
L-DOS47 and V-DOS47); (iii) that any transactions contemplated
herein are completed; and (iv) those risks and uncertainties
affecting Helix as more fully described in Helix’s most recent
Annual Information Form, which is available at www.sedar.com
(together, the “Helix Risk Factors”). Certain material factors and
assumptions are applied in making the forward-looking statements,
including, without limitation, that sufficient financing will be
obtained in a timely manner to allow Helix to continue operations
and implement its clinical trials in the manner and on the
timelines anticipated and that the Helix Risk Factors will not
cause Helix’s actual results or events to differ materially from
the forward-looking statements. These cautionary statements qualify
all such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions, opinions, plans and expectations
of Helix’s management on the date of this news release, and the
Company does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions, opinions, plans or expectations, or other
circumstances change, except as required by law.
Investor Relations
Helix BioPharma Corp.9120 Leslie Street, Suite 205Richmond Hill,
Ontario, L4B 3J9Tel: 905-841-2300ir@helixbiopharma.com
Alpha Bronze, LLCMr. Pascal NigenPhone: + 1 (917)
385-2160helix@alphabronze.net
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Dez 2023 bis Dez 2024